Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stephane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha L. Arellano, William B. Donnellan, Harry P. Erba, Gabriel N. Mannis, Daniel A Pollyea, Anthony S. Stein, Geoffrey L. Uy, Justin M. Watts, Amir T. Fathi, Hagop M. Kantarjian, Martin S. Tallman, Sung Choe, David Dai, Bin Fan, Hongfang Wang, Vickie Zhang, Katharine E. Yen, Stephanie M. Kapsalis, Denice Hickman, Hua Liu, Samuel V. Agresta, Bin Wu, Eyal C. Attar, Richard M. Stone
Institutions: Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, The Ohio State University Wexner Medical Center, Johns Hopkins Hospital, Northwestern University, Winship Cancer Institute, Sarah Cannon, University of Alabama at Birmingham, UCSF Helen Diller Family Comprehensive Cancer Center, University of Colorado Anschutz, University of Colorado Denver, City Of Hope National Medical Center, Washington University in St. Louis, University of Miami, Sylvester Comprehensive Cancer Center, Massachusetts General Hospital, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2906252871